<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5135">
  <stage>Registered</stage>
  <submitdate>31/08/2015</submitdate>
  <approvaldate>31/08/2015</approvaldate>
  <nctid>NCT02538848</nctid>
  <trial_identification>
    <studytitle>Study of HTD4010 in Healthy Volunteers</studytitle>
    <scientifictitle>A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>4010.PCT001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes Mellitus</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - HTD4010

Experimental: 50mg in SAD - single dose of 50mg HTD4010 or placebo injectable in healthy volunteers

Experimental: 100mg in SAD - single dose of 100mg HTD4010 or placebo injectable in healthy volunteers

Experimental: 200mg in SAD - single dose of 200mg HTD4010 or placebo injectable in healthy volunteers

Experimental: 300mg in SAD - single dose of 300mg HTD4010 or placebo injectable in healthy volunteers


Treatment: drugs: HTD4010
injectable solution

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence, severity and causality of adverse events</outcome>
      <timepoint>One day in SAD</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>For volunteers in SAD:

        

          1. Body mass index (BMI) =18.0 to = 30.0 kg/m2

          2. Non-diabetic, fasting plasma glucose &lt; 5.6 mmol/L

          3. Females must be non-pregnant and non-lactating, and either surgically sterile (e.g.,
             tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy) or
             post-menopausal for =12 months.

             Males must be surgically sterile, abstinent or if engaged in sexual relations of
             child-bearing potential, the participant and his partner must be using an acceptable,
             highly effective, contraceptive method from screening and for a period of 60 days
             after the last dose of Study Drug.

          4. Ability to provide written informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Systolic blood pressure &gt;160 mmHg and/or diastolic blood pressure &gt;90 mmHg at
             screening.

          2. Pregnant or lactating women

          3. Participation in an investigational study within 30 days prior to dosing or 5
             half-lives within the last dose of investigational product whichever is longer.

          4. Current use of any prescription or over-the-counter (OTC) medications, including
             herbal products and supplements, within 14 days prior to Day 1 or 5 half-lives,
             whichever is longer. Use of =2g paracetamol per day is allowed prior to and during the
             study at Investigator discretion.

          5. Any use of non-steroid anti-inflammatory drugs (NSAIDs) within 7 days prior to dosing.

          6. History of any major surgery within 6 months prior to Screening

          7. History of any serious adverse reaction or hypersensitivity to any of the product
             components.

          8. Use of parenterally administered proteins or antibodies within 12 weeks of screening.

        etc.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>32</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Linear Clinical Research Limited - Perth</hospital>
    <postcode>WA6009 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>HighTide Biopharma Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate safety and tolerability of HTD4010 after single ascending doses (SAD) in
      healthy volunteers</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02538848</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Janakan Krishnarajah, Doctor</name>
      <address>Linear Clinical Research Limited</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>